Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Exercise associated or not to the intake of Eurycoma longifolia improves strength and cardiorespiratory fitness in men with androgen deficiency.

  • 2021-01-05
  • Complementary therapies in clinical practice 42
    • Alice Erwig Leitão
    • Melissa de Carvalho Souza Vieira
    • Diogo Almeida Gomes
    • Leonessa Boing
    • Andreia Pelegrini
    • Edson Luiz
    • Adriana Coutinho de Azevedo Guimarães

Study Design

Type
Randomized Controlled Trial (RCT)
Sample size
n = 12
Population
45 subjects (47.6 ± 5.2 years) men with the androgen deficiency of aging male (ADAM)
Methods
Randomized, double-blinded, placebo controlled clinical trial, 6 months of concurrent training (CT) associated with Eurycoma longifolia (EL) supplementation
Blinding
Double-blind
Duration
6 months
Funding
Unclear
This study aims to analyze the effects of a concurrent training (CT) associated with Eurycoma longifolia (EL) supplementation on the muscle strength, cardiorespiratory fitness, and symptomatology score of men with the androgen deficiency of aging male (ADAM). Forty-five subjects (47.6 ± 5.2 years) were included in the study. The randomized, double-blinded, placebo controlled clinical trial lasted for 6 months. Participants were randomized into four groups, control (C; n = 12); EL (n = 11); CT (n = 11); and CT + EL (n = 11). Along this period, the isokinetic peak torque of the knee extensors increased in the CT (14%) and CT + EL (17%) groups (p = 0.040; p = 0.006, respectively), while the isokinetic peak torque of knee flexion increased in the CT + EL group only (p < 0.05). For all participants, testosterone levels were correlated with isokinetic peak torque of knee extension (r = 0.517, p = 0.001) and flexion (r = 0.362, p = 0.028). Subjects of the CT (27.3%) and CT + EL (36.1%) groups decreased the symptomatology of ADAM (p = 0.005). This study demonstrated the benefits of CT and EL consumption as a non-pharmacological treatment for ADAM.

Research Insights

Back to top